Printer Friendly

Amgen agrees purchase of Iceland's deCODE Genetics.


11 December 2012 a[euro]" US biotechnology company Amgen Inc (NASDAQ:AMGN) has signed a definitive agreement for the acquisition of Icelandic human genetics specialist deCODE Genetics Inc.

The change in ownership will be effected through an all-cash deal worth USD415m (EUR231m), the buyer said.

The transaction has received unanimous approval from Amgena[euro](tm)s board and is seen as closing before the start of 2013. Amgen said that no regulatory clearance was required for the deal to be wrapped up.

Amgena[euro](tm)s president and chief executive Robert A. Bradway described deCODE as a preeminent force in the field of human genetics, with capabilities that would help Amgen achieve its objectives in the identification and validation of human disease targets. With the addition of deCODE, Amgen is making the right move in the pursuit of its goal to develop relevant medicines fast and avoid getting involved in projects with less chance of success, Bradway said.Country: IcelandSector: BiotechnologyTarget: deCODE Genetics IncBuyer: Amgen IncDeal size in USD: 415mType: Corporate acquisitionStatus: Agreed

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Date:Dec 10, 2012
Previous Article:M&A Navigator: Deal pipeline - 10 December.
Next Article:GI Partners disposes of Plum Healthcare through sale to Bay Bridge Capital.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters